MRC1 and endometrial cancer: We included 147 endometrial cancer patients (38 in the adenomyosis group and 109 in the no adenomyosis group) and we found no significant difference in the prevalence of p53-abn (p = 1.000) and MMR-d (p = 0.2880) signatures between the two groups.